KRIYA-748 / Kriya Therap - LARVOL DELTA

Development of a stable and CNS-tolerant AAV5 formulation for KRIYA-748 (ASGCT 2026) - "Consequently, active ingredient concentration must be an important consideration when designing product presentations for both long-term stability and patient administration. The proposed formulation accomplishes both goals of remaining stable under stress and has no known incompatibility with CNS administration."

Gene Therapies • Neuralgia

RELIEF: RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Kriya Therapeutics, Inc.

New P1/2 trial • Neuralgia • Pain

Assay Validation and Clinical Sample Stability of Recombinant AAV Vector in Five Human Shedding Matrices (ASGCT 2024) - "KRIYA-748 is an AAV-based vector that delivers a gated ion channel to the trigeminal nerve for trigeminal neuralgia, a disease characterized by frequent, debilitating facial pain attacks. Once expressed, the channel is activated by orally-administered varenicline ("Chantix®") leading to reduced excitation of transduced neurons... Ten validation runs were performed with serially diluted DNA standards, negative controls, and QCs, plated in the presence of DNA extracted from each of the shedding matrices evaluated. Each completed run met the validation acceptance criteria for target gene amplification. The ULOQ, LLOQ, and LOD were 108, 50, and 10 double stranded copies per reaction, respectively."

Clinical • Gene Therapies • Neuralgia • Pain